Sacituzumab or Chemo in First-Line TNBC: Which Is Better?

Chemo-Free Doublet in First-Line Boosts PFS in Triple-Negative Breast Cancer

(MedPage Today) — CHICAGO — Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line treatment significantly reduced the risk of progression or death in patients with PD-L1-positive… Source link : https://www.medpagetoday.com/meetingcoverage/asco/115829 Author : Publish date : 2025-05-31 12:00:00 Copyright for syndicated content belongs to the linked Source. The post Chemo-Free Doublet in…

Breaking Ground in Breast Cancer: A New Standard in TNBC, a New Way to Target ESR1

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer (TNBC) and estrogen receptor–positive tumors.

Sacituzumab or Chemo in First-Line TNBC: Which Is Better?

Pembrolizumab with sacituzumab govitecan instead of chemotherapy led to improved progression-free survival in PD-L1-postive locally advanced or metastatic triple-negative breast cancer. Medscape Medical News